跳至主要内容
临床试验/CTRI/2019/07/020113
CTRI/2019/07/020113招募中未知

A PROSPECTIVE OBSERVATIONAL STUDY COMPARING RITUXIMAB , TACROLIMUS AND MODIFIED PONTICELLI REGIMEN IN THREE DIFFERENT TREATMENT COHORTS OF PRIMARY MEMBRANOUS NEPHROPATHY

IPGMER AND SSKM HOSPITAL KOLKATA0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Biopsy proven PMN of age group 18-70 years, fulfilling the criteria for immunosuppression therapy .
  • 2.Fulfilling the criteria for immunosuppression therapy - Urinary protein excretion persistently exceeds 4 g/d AND remains at over 50% of the baseline value AND does not show progressive decline during antihypertensive and antiproteinuric therapy during an observation period of at least 6 months or severe disabling or life threatning symptoms related to the nephrotic syndrome.
  • 3.SCr has risen by 30% or more within 6 to 12 months from the time of diagnosis but the eGFR is not less than 25 ml/min per 1.73m2 AND this change is not explained by superimposed complications.

排除标准

  • 1.Patients with active infection.
  • 2.Diabetes mellitus.
  • 3.Hepatitis B/C or human immunodeficiency virus infection.
  • 4.Liver function abnormalities.
  • 5.Neoplasia.
  • 6.Chronic Diarrhoea.
  • 7.Pregnancy.
  • 8.Patients not willing for contraception.

研究者

发起方
IPGMER AND SSKM HOSPITAL KOLKATA

相似试验